Prevention & lipidsMeta-analysis
Small Interfering RNA for LDL-Cholesterol Reduction
- Systematic Review and Meta-Analysis of Randomized Controlled Trials
- random-effects model using the generic inverse variance method
Authors' conclusion
Inclisiran achieves substantial reductions in LDL-C across diverse patient populations. Its twice-yearly dosing schedule and small interfering RNA mechanism of action position inclisiran as a promising long-term lipid-lowering therapy, with potential for broader implementation as clinical experience and outcomes data continue to evolve. (Small Interfering RNA Therapy for LDL-Cholesterol Reduction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials; CRD420251178991.).
Study context
- Population
- Participants in randomized controlled trials comparing inclisiran with placebo, across diverse patient populations
- Participants
- 6,355 Nine randomized control trials
- Comparison
- inclisiran vs placebo in reducing low-density lipoprotein cholesterol (LDL-C) levels
- Outcome
- Mean percent change in LDL-C from baseline
Pooled result
As reported in the abstract
Pooled mean LDL-C reduction
−48.77% %
95% CI −54.26 to −43.27
P < 0.001
Inclisiran vs placebo
pooled mean LDL-C reduction −48.77% % (95% CI −54.26 to −43.27); P < 0.001
Further pooled results
Follow-up duration
- Follow-up ranged from
- 0.5 to 1.5 years
Heterogeneity
- Significant heterogeneity
- I2 = 95%
- largely attributable to differences in background lipid-lowering therapy and treatment intensification
Original publication
Small Interfering RNA for LDL-Cholesterol Reduction. JACC Adv. doi:10.1016/j.jacadv.2026.102932
Summarised from the published abstract; every number is checked against it